Shares of FibroBiologics, Inc. (FBLG) are up by 22% following the announcement that the company has been granted a new U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis.
The patent, issued on February 10, 2026, strengthens FibroBiologics' intellectual property portfolio in regenerative medicine and bone-related disorders. It covers methods of treating osteoporosis and other bone diseases through the administration of fibroblast cells, including modified fibroblasts designed to inhibit bone-resorbing osteoclasts and promote bone-building osteoblasts.
CEO Pete O'Heeron described the patent as a "bold step forward" in the company's mission to leverage fibroblasts as therapeutic agents capable of tackling both inflammation and bone degeneration.
Osteoporosis, a chronic condition that weakens bones and increases fracture risk, affects millions worldwide, and the company sees fibroblast therapy as a potential breakthrough in addressing this unmet medical need.
FibroBiologics, based in Houston, holds more than 270 issued and pending patents across areas such as wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, and cancer. The latest patent adds to its pipeline of fibroblast-based therapies aimed at chronic diseases.
FBLG has traded between $0.22 and $1.53 over the past year. The stock is currently trading at $0.40, up 22%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.